Search results: (10000)
News Expression of PD-L1 as a Predictive Biomarker for Therapy Selection in mRCC
A newly published systematic review and meta-analysis of studies involving patients with metastatic renal cell carcinoma (mRCC) evaluates the predictive significance of PD-L1 expression in the treatment with immune checkpoint inhibitors.
News Negative Symptoms of Schizophrenia and Their Assessment
Schizophrenia is a serious psychiatric disorder with a prevalence of up to 1%. It can manifest with both negative and positive symptoms. We briefly summarize the clinical assessment and rating scales of negative symptoms in the following text.
News Von Willebrand Disease as a Cause of Abnormal Uterine Bleeding
Abnormal uterine bleeding constitutes a large portion of complaints among women of reproductive age. This type of bleeding is typical for von Willebrand disease (vWD), but also for other types of coagulation disorders. So, is vWD more frequent in women with abnormal uterine bleeding than in the general population?
News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
News Dabigatran Etexilate in the Treatment of Acute Thromboembolic Disease in Children
Until now, standard anticoagulants such as low-molecular-weight heparin or unfractionated heparin and others have been used in pediatric patients for the treatment of thromboembolism. The study presented below aimed to determine whether dabigatran could be the drug of the future in the treatment of pediatric patients with thromboembolism.
News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?
Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.
News Dust Mite Allergies: Common Does Not Mean Trivial
Dust mite allergies are almost ubiquitous problems that we perceive as part of the 'broader norm.' However, patients do not see it this way, so we should not lose sight of it.
News Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple sclerosis (MS). Regarding the course, form, and severity of MS, their target groups are comparable in their characteristics. These DMDs are therefore ideal candidates for mutual comparison. Swedish authors decided to compare their effectiveness based on data from real clinical practice obtained through the Swedish National Registry.
News MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?
What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from the broader spectrum of neuromyelitis optica (NMOSD) in Czechia? And which risk factors pertain to this specific population? Data from the ReMuS registry, summarized in an article by Czech authors recently published in the journal Multiple Sclerosis and Related Disorders, revealed this and more. We offer a unique insight into the issue of COVID-19 in these patients in our conditions.
News Key for Patients with PBC are Timely Diagnosis and Assessment of Therapy Effectiveness
Primary biliary cholangitis (PBC) cannot be cured. It progresses slowly and over several decades leads to liver cirrhosis with all its potential consequences, including possible transplantation and the risk of premature death. The foundation of PBC pharmacotherapy is ursodeoxycholic acid (UDCA) and in recent years, obeticholic acid (OCA) has also been available, which European and Czech guidelines recommend as the second-line treatment. One of the symposiums at this year's XLVIII May Hepatology Days also focused on PBC and its therapy, including experiences from Czech practice.
News OCA in Second-Line Treatment of PBC: Analysis Results and Real-World Data
Ursodeoxycholic acid (UDCA) is the cornerstone treatment for PBC according to the guidelines of the European Association for the Study of the Liver (EASL). However, many patients (25–50%) do not achieve an adequate response to it, and some patients develop intolerance leading to the necessity of discontinuation (in the phase III POISE study, this concerned 7% of participants). Then, obeticholic acid (OCA) is indicated, which is recommended as the only registered second-line treatment option for PBC by current professional guidelines both European (EASL 2017) and Czech (2018). The latest data on OCA from clinical studies as well as real-world practice was also presented at this year's XLVIII May Hepatology Days.
News Experiences with treating PBC with obeticholic acid in Brno's CKTCH
MUDr. Libuše Husová, Ph.D., shared the current insights from the therapy of patients with primary biliary cholangitis (PBC) using obeticholic acid (OCA) gained at the Center for Cardiovascular and Transplantation Surgery in Brno (CKTCH) during the XLVIII May Hepatology Days.
News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.
News Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had asthma and/or chronic rhinosinusitis, investigated how clinically and statistically significant the benefit of dupilumab is for all these 3 conditions in comparison with a placebo.
News The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor
Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G protein. The authors of the presented study found that the anti-inflammatory and renoprotective effect of candesartan persists even when the receptor is completely blocked. The aim of the further study was to clarify this mechanism - independent of AT1R.